Skip to content
10-K

Annual Report

Rapid Therapeutic Science Laboratories, Inc.

0001393905-22-000069

← back to feed
Filed
Mar 16, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2021 · Mar 16, 2022 193.67M sh
Net Income FY 2021 · Dec 31, 2021 −$2.87M
Net Income FY 2021 · Dec 31, 2020 −$2.05M
Capex FY 2021 · Dec 31, 2020 $106.74K
Operating Cash Flow FY 2021 · Dec 31, 2020 −$1.72M
Cash And Equivalents FY 2021 · Dec 31, 2020 $499.15K
Cash And Equivalents restated FY 2021 · Dec 31, 2019 $136.22K
Stockholders Equity FY 2021 · Dec 31, 2020 −$11.2K
Current Liabilities FY 2021 · Dec 31, 2020 $1.21M
Total Liabilities FY 2021 · Dec 31, 2020 $1.52M
Current Assets FY 2021 · Dec 31, 2020 $685.95K
Total Assets FY 2021 · Dec 31, 2020 $1.51M
Sga Expense FY 2021 · Dec 31, 2020 $2.02M
Gross Profit FY 2021 · Dec 31, 2020 $111.52K
Cost Of Revenue FY 2021 · Dec 31, 2020 $19.39K
Revenue FY 2021 · Dec 31, 2020 $130.92K